Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMOTION: Tocilizumab for Anemia and Fatigue in RA
NCT00951275Phase 3Completed
- Sponsor
- Roche
- Start
- Oct 2009
- Primary completion
- Jul 2011
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tocilizumab in rheumatoid arthritis (RA), sponsored by Roche. Primary endpoints: Improvement of Anemia Assessed as Change From Baseline in Hemoglobin at 4 weeks and Improvement in Fatigue Assessed as Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scores at 4 weeks. Started Oct 2009; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00951275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00951275.